Breakthrough research featuring contributions from Eric Arias, MD, who serves as the medical director of CarePoint’s Neurosurgery and Spine division, was recently published in the New England Journal of Medicine.
A landmark study, the STEM trial, which involved 310 patients, is significant because it provides strong evidence for the benefit of middle meningeal artery (MMA) embolization in the treatment of chronic subdural hematoma (cSDH). It points to a potential paradigm shift in cSDH management, which could move toward less invasive options. The trial results will likely inform clinical guidelines and practice, promoting the use of adjunctive MMA embolization to improve outcomes for patients with cSDH.
What Is the STEM Trial?
The STEM trial investigated the effectiveness of middle meningeal artery (MMA) embolization as an adjunct to standard treatment for chronic subdural hematoma, a condition most common in older adults. Traditionally, cSDH has been managed through surgical evacuation or conservative care, both of which carry a high risk of recurrence and complications.
This landmark study enrolled 310 patients and compared outcomes between those receiving standard treatment alone and those receiving standard treatment plus MMA embolization. The breakthrough research results were striking:
- Treatment failure occurred in only 16% of patients receiving embolization, compared to 36% in the control group.
- No increase in major disabling stroke or short-term mortality was observed.
These findings suggest that MMA embolization significantly reduces recurrence rates without adding risk—marking a potential paradigm shift in cSDH management.
Why This Matters for Patients in Denver
For patients in the Denver metropolitan area, this research means access to less invasive, evidence-based options for treating chronic subdural hematoma. Dr. Arias’ dual training in neurosurgery and endovascular neuroradiology uniquely positions him to offer both surgical and endovascular treatments, including MMA embolization, from his Englewood practice.
Dr. Arias’ Role and Expertise
As a recognized Top Doctor in Neurosurgery by Castle Connolly and 5280 Magazine (2024 and 2025), Dr. Arias is committed to advancing neurosurgical care through research and innovation. His involvement in the STEM trial underscores his dedication to improving patient outcomes and shaping the future of neurosurgery.
Looking Ahead
The STEM trial’s findings will likely influence clinical guidelines and encourage broader adoption of MMA embolization as an adjunctive therapy. For patients in Colorado, this means safer, more effective treatment options delivered by a trusted expert.
You can read the full study here.
